TTI-102

About Tvardi Therapeutics

Tvardi Therapeutics is a Houston-based biotech focused on developing oral STAT3 inhibitors to treat fibrosis-driven, inflammatory, and proliferative diseases. Founded in 2017, the company has progressed its lead asset, TTI-101, into Phase 2 trials for IPF and liver cancer. Its strategy leverages a novel, direct STAT3 inhibition platform with broad therapeutic potential, recently bolstered by a 2025 merger with Cara Therapeutics to enhance resources and pipeline depth.

Therapeutic Areas